Liu Xiaolin

Liu Xiaolin (chief executive) discloses dealings in China Biotech Services Holdings Ltd. to HKEX. The record holds 45 filings, for trades running from 7 August 2017 to 15 October 2026.

Both buying and selling appear: 20 purchases worth €12.5M, against 12 sales worth €41.2M. The totals do not cover 12 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 2 purchases and no sales.

Half of the purchases are above €7,854 and half below. None of the 14 purchases we analysed coincided with buying by another insider of the same company within 30 days. Looking at 14 purchases old enough to measure, the stock rose over the following 90 days in 14% of cases; the median change was -27.3%. This is a record of the past, not a forecast.

The record was last updated on 21 October 2026 with an open-market purchase (€2,764) in China Biotech Services Holdings Ltd. Typically, a trade is published a median of 3 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done. Source: insider filings from HKEX. Past trades are no guide to future returns.